HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Organic Standards Board to enforce claims

This article was originally published in The Rose Sheet

Executive Summary

In a 12 to 1 vote the National Organic Standards Board decided it will urge the agency to "enforce the law for organic personal care just like they do for organic food," taking action against brands that claim to be organic but are not certified to standards established under the National Organic Program, according to Nov. 5 release by the Organic Consumers Association. "Brands that are using the word 'organic' improperly should be on notice that USDA enforcement is imminent," said OCA Executive Director Ronnie Cummins, who added that during the NOSB meeting this week NOP Director Miles McEvoy announced a "new age of enforcement" in organic. Cummins said he believes NOP will make "organic cosmetics fraud a top priority." OCA has kicked off its boycott of brands it deems misleadingly marketed as organic, coupled with a "buycott" of "honest" organic brands (1"The Rose Sheet" Sept. 28, 2009). Lists of brands in those categories are posted on the association's Web site

You may also be interested in...



Countdown To Boycott: OCA Confronts Organic Firms, Retailers At Expo East

Roughly a month before its planned launch of a boycott against organic "cheater" brands, the Organic Consumers Association made final appeals to marketers and looked to influence retailers at the natural product industry's leading tradeshow

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel